Tags

Type your tag names separated by a space and hit enter

Is there a role for newer biomarkers in chronic kidney disease-mineral and bone disorder management?
Nephrology (Carlton). 2017 Mar; 22 Suppl 2:14-18.N

Abstract

The current management of Chronic Kidney Disease-Mineral Bone Disorder (CKD-MBD) relies largely on clinical judgement and assessment of biochemical parameters including serum calcium, phosphate and intact parathyroid hormone concentrations. In the past two decades, there has been a leap in the understanding of the pathophysiology of CKD-MBD, leading to the discovery of novel biomarkers. The potential utility of these markers in this clinical setting is an area of intense investigation. In the absence of any guidelines aiding the clinician's understanding and application of these markers, we summarise the current available literature surrounding fibroblast growth factor-23, α-Klotho, sclerostin and serum calcification propensity testing and their respective assays in the context of CKD-MBD management.

Authors+Show Affiliations

Department of Nephrology, The Royal Melbourne Hospital, Parkville, Victoria, Australia. Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia.Department of Nephrology, The Royal Melbourne Hospital, Parkville, Victoria, Australia. Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

28429560

Citation

Tan, Sven-Jean, and Michael Mx Cai. "Is There a Role for Newer Biomarkers in Chronic Kidney Disease-mineral and Bone Disorder Management?" Nephrology (Carlton, Vic.), vol. 22 Suppl 2, 2017, pp. 14-18.
Tan SJ, Cai MM. Is there a role for newer biomarkers in chronic kidney disease-mineral and bone disorder management? Nephrology (Carlton). 2017;22 Suppl 2:14-18.
Tan, S. J., & Cai, M. M. (2017). Is there a role for newer biomarkers in chronic kidney disease-mineral and bone disorder management? Nephrology (Carlton, Vic.), 22 Suppl 2, 14-18. https://doi.org/10.1111/nep.13015
Tan SJ, Cai MM. Is There a Role for Newer Biomarkers in Chronic Kidney Disease-mineral and Bone Disorder Management. Nephrology (Carlton). 2017;22 Suppl 2:14-18. PubMed PMID: 28429560.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Is there a role for newer biomarkers in chronic kidney disease-mineral and bone disorder management? AU - Tan,Sven-Jean, AU - Cai,Michael Mx, PY - 2017/4/22/entrez PY - 2017/4/22/pubmed PY - 2018/2/27/medline KW - calcification propensity KW - chronic kidney disease KW - fibroblast growth factor-23 KW - sclerostin KW - soluble klotho SP - 14 EP - 18 JF - Nephrology (Carlton, Vic.) JO - Nephrology (Carlton) VL - 22 Suppl 2 N2 - The current management of Chronic Kidney Disease-Mineral Bone Disorder (CKD-MBD) relies largely on clinical judgement and assessment of biochemical parameters including serum calcium, phosphate and intact parathyroid hormone concentrations. In the past two decades, there has been a leap in the understanding of the pathophysiology of CKD-MBD, leading to the discovery of novel biomarkers. The potential utility of these markers in this clinical setting is an area of intense investigation. In the absence of any guidelines aiding the clinician's understanding and application of these markers, we summarise the current available literature surrounding fibroblast growth factor-23, α-Klotho, sclerostin and serum calcification propensity testing and their respective assays in the context of CKD-MBD management. SN - 1440-1797 UR - https://www.unboundmedicine.com/medline/citation/28429560/Is_there_a_role_for_newer_biomarkers_in_chronic_kidney_disease_mineral_and_bone_disorder_management DB - PRIME DP - Unbound Medicine ER -